Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.74) earnings per share for the quarter, Zacks reports.
Scinai Immunotherapeutics Price Performance
Shares of NASDAQ:SCNI opened at $3.22 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.35. The business’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $5.03. The stock has a market cap of $1.67 million, a PE ratio of -3.04 and a beta of 2.08. Scinai Immunotherapeutics has a one year low of $2.15 and a one year high of $17.20.
Institutional Trading of Scinai Immunotherapeutics
A hedge fund recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its holdings in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. 58.41% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
View Our Latest Report on SCNI
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.
Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.
See Also
- Five stocks we like better than Scinai Immunotherapeutics
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
